Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yervoy in advanced synovial sarcoma
NCT00140855Phase 2Terminated
- Sponsor
- Ludwig Cancer Research
- Start
- Jun 2005
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab in synovial sarcoma (SS), sponsored by Ludwig Cancer Research. Primary endpoint: Best Tumor Response by RECIST at 10 weeks. Started Jun 2005; status: terminated.
02
Drugs
ipilimumab
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT00140855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140855.